Bulløse hudsygdomme

Jeanette Kaae; Rikke Bech; Elisabeth Hjardem Taudorf; Shiva Yazdanyar; Christian Vestergaard; Hans Christian Ring; Gregor B. E. Jemec

Bulløse hudsygdomme

Jeanette Kaae, Rikke Bech, Elisabeth Hjardem Taudorf, Shiva Yazdanyar, Christian Vestergaard, Hans Christian Ring, Gregor B. E. Jemec

Dermatologisk Afdeling

Publikation: Bidrag til tidsskrift › Review › Forskning › peer review

Abstract

This review finds that topical corticosteroids and systemic corticosteroids are the mainstays of initial treatment for bullous pemphigoid and pemphigus diseases. Additional immunomodulatory therapies such as methotrexate, azathioprine and mycophenolatmofetil should be added early during treatment to minimize the adverse effects of chronic corticosteroid therapy and to augment improvement in the disease. Rituximab is a first-line immunomodulatory treatment for moderate to severe pemphigus disease.

Bidragets oversatte titel	Bullous skin diseases
Originalsprog	Dansk
Artikelnummer	V06220400
Sider (fra-til)	774-778
Antal sider	5
Tidsskrift	Ugeskrift for Laeger
Vol/bind	185
Udgave nummer	8
Status	Udgivet - 17 apr. 2023

Emneord

Autoimmune Diseases
Azathioprine/adverse effects
Glucocorticoids
Humans
Methotrexate/adverse effects
Pemphigus/chemically induced
Rituximab/therapeutic use
Skin Diseases, Vesiculobullous/chemically induced

Adgang til dokumentet

https://ugeskriftet.dk/videnskab/bullose-hudsygdomme-0

Citationsformater

@article{14d8d3b550b1435a8970668a48b02786,

title = "Bull{\o}se hudsygdomme",

abstract = "This review finds that topical corticosteroids and systemic corticosteroids are the mainstays of initial treatment for bullous pemphigoid and pemphigus diseases. Additional immunomodulatory therapies such as methotrexate, azathioprine and mycophenolatmofetil should be added early during treatment to minimize the adverse effects of chronic corticosteroid therapy and to augment improvement in the disease. Rituximab is a first-line immunomodulatory treatment for moderate to severe pemphigus disease.",

keywords = "Autoimmune Diseases, Azathioprine/adverse effects, Glucocorticoids, Humans, Methotrexate/adverse effects, Pemphigus/chemically induced, Rituximab/therapeutic use, Skin Diseases, Vesiculobullous/chemically induced",

author = "Jeanette Kaae and Rikke Bech and Taudorf, \{Elisabeth Hjardem\} and Shiva Yazdanyar and Christian Vestergaard and Ring, \{Hans Christian\} and Jemec, \{Gregor B. E.\}",

year = "2023",

month = apr,

day = "17",

language = "Dansk",

volume = "185",

pages = "774--778",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "8",

}

TY - JOUR

T1 - Bulløse hudsygdomme

AU - Kaae, Jeanette

AU - Bech, Rikke

AU - Taudorf, Elisabeth Hjardem

AU - Yazdanyar, Shiva

AU - Vestergaard, Christian

AU - Ring, Hans Christian

AU - Jemec, Gregor B. E.

PY - 2023/4/17

Y1 - 2023/4/17

N2 - This review finds that topical corticosteroids and systemic corticosteroids are the mainstays of initial treatment for bullous pemphigoid and pemphigus diseases. Additional immunomodulatory therapies such as methotrexate, azathioprine and mycophenolatmofetil should be added early during treatment to minimize the adverse effects of chronic corticosteroid therapy and to augment improvement in the disease. Rituximab is a first-line immunomodulatory treatment for moderate to severe pemphigus disease.

AB - This review finds that topical corticosteroids and systemic corticosteroids are the mainstays of initial treatment for bullous pemphigoid and pemphigus diseases. Additional immunomodulatory therapies such as methotrexate, azathioprine and mycophenolatmofetil should be added early during treatment to minimize the adverse effects of chronic corticosteroid therapy and to augment improvement in the disease. Rituximab is a first-line immunomodulatory treatment for moderate to severe pemphigus disease.

KW - Autoimmune Diseases

KW - Azathioprine/adverse effects

KW - Glucocorticoids

KW - Humans

KW - Methotrexate/adverse effects

KW - Pemphigus/chemically induced

KW - Rituximab/therapeutic use

KW - Skin Diseases, Vesiculobullous/chemically induced

M3 - Review

C2 - 36254827

SN - 0041-5782

VL - 185

SP - 774

EP - 778

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 8

M1 - V06220400

ER -

Bulløse hudsygdomme

Abstract

Emneord

Adgang til dokumentet

Fingeraftryk

Citationsformater